Innovative Industrial Properties Inc vs Revvity Inc — how do they compare? Innovative Industrial Properties Inc trades at $51.83 (market cap $1.43B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 11.9× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (14.64%). Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and Revvity Inc for 12 Days on average.
| IIPR | RVTY | |
|---|---|---|
Market Cap | $1.43B | $16.98B |
Volume | 394,222 | 1,456,900 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $157.36 |
52-Week Low | $44.58 | $82.26 |
Typical Hold Time | 86 Days | 12 Days |
Enterprise Value | $1.96B | $19.30B |
Dividend Yield | 14.64% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.92, up 1.35% with bearish technical signals but attractive valuation metrics including P/E of 11.75 and P/B of 0.83. The REIT reported mixed Q2 2026 earnings, beating expectations with $1.36 EPS versus $1.02 expected, while revenue declined to $266M in 2025. Recent news highlights a $245M mezzanine loan commitment and a $1.90 quarterly dividend, though cash flow turned negative in 2025.
The stock presents a high-yield opportunity with 13%+ dividend yield but faces tenant default risks and sector volatility. Analyst consensus is mixed with 36% buy ratings and $84.67 price target suggesting 63% upside, though technical indicators remain bearish. Regulatory catalysts and balance sheet strength provide potential upside amid cannabis REIT sector challenges.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →